Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Clover Health Stock Erupts 14% on Smaller-than-expected Loss, Analyst Sees 'Clean Quarter'
Published May 10, 2022 05:04AM ET
Updated May 10, 2022 09:36AM ET
© Reuters. Clover Health (CLOV) Stock Erupts 14% on Smaller-than-expected Loss, Analyst Sees 'Clean Quarter'
Shares of Clover Health (NASDAQ:CLOV) are up more than 14% in premarket trading Tuesday after the company reported better-than-expected Q1 revenue.
CLOV reported Q1 revenue of $874.4 million, while analysts were looking for $790.3 million. Net loss totaled $75.3 million in the period. CLOV reported an adjusted EBITDA loss of $71.8 million, compared to the expected loss of $112.1 million.
For the full fiscal year, Clover Health expects revenue in the range of $3 billion to 3.4 billion, compared to the consensus estimates of $3.24 billion.
“2022 is off to a strong start, led by significant year-over-year revenue growth and quarter-over-quarter margin improvements in insurance (medicare advantage) and non-insurance (direct contracting),” said Clover Health CEO Vivek Garipalli.
Bank of America analyst Kevin Fischbeck reiterated an Underperform rating on CLOV stock but said results demonstrated “a first step to restoring confidence.”
“The focus is shifting to going deeper in existing markets, where growth is likely slower but the path to profitability is clearer. Overall, Q1 showed progress and is a good first step towards restoring confidence in the trajectory, but similar to CLOV’s own outlook we remain cautious until the outperformance is sustained throughout the year,” Fischbeck said in a client note.
Cowen analyst Gary Taylor reiterated a Market Perform rating and a $3.00 per share price target. The analyst still expects CLOV to raise equity capital this year.
“We are skeptical regarding CLOV’s core business thesis; that overlaying Clover Assistant (CA) on top of unmanaged FFS physician practices will yield best-in-class care management and per-capita medical costs. The company’s MA business risks all on this thesis. Further, CLOV is quadrupling its total actuarial risk profile by 2022 via participation in CMS’ new and untested Direct Contracting (DC) program,” Taylor wrote in a memo.
By Senad Karaahmetovic
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.